Barcelona snapshots

Prof. Christoph Correll

Christoph Correll psychiatrist Controversies Psiquiatry Barcelona
Charité Universitätsmedizin Berlin, Germany & Zucker School of Medicine at Hofstra/Northwell, USA
Talk Prevention of psychosis in children and adolescents
Date Friday, September 17th, 2021
Time 15:30 - 16:15
Round Table 4. Psychotic disorders


Christoph Correll is Professor of Psychiatry at The Zucker School of Medicine at Hofstra/Northwell, New York, USA, and also Professor and Chair of the Department of Child and Adolescent Psychiatry, Charité University Medicine, Berlin, Germany. He completed his medical studies at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at The Zucker Hillside Hospital in New York. Since 1997, he has been working and conducting research in New York, USA, and since 2017 he is also working in Germany again.

Prof. Correll's research and clinical work focus on the identification, characterization and treatment of youth and adults with severe mental illness, including psychotic and mood disorders. He further focuses on psychopharmacology, epidemiology, clinical trials, meta-analyses, the risk–benefit evaluation of psychotropic medications, and the interface between physical and mental health.

He has authored over 650 journal articles, served on several expert consensus panels, and received over 40 research awards for his work.

Since 2014, the year of inception of this metric, he has been listed every year by Clarivate/Web of Science as one of the "most influential scientific minds" and "top 1% cited scientists in the area of psychiatry".

Additionally, he has been holding numerous Expertscape rankings, such as 15 topics ranked as "Expert" (among the top 1% cited scientists), and 24 topics ranked as "World Expert" (among the top 0.1% cited scientists), including in March 2021 for example ranked as the #1 expert for:
  1. Central nervous system agents, out of 308,311 scientists (
  2. Psychotropic drugs, out of 131,808 scientists (
  3. Schizophrenia Spectrum and Other Psychotic Disorders, out of 94,268 scientists (
  4. Schizophrenia, out of 90,874 scientists (
  5. Tranquilizing agents, out of 71,122 scientists ( agents)
  6. Weight gain, out of 68,578 scientists (
  7. Delayed-action preparations out of 68,517 ranked scientists (
  8. Antipsychotics, out of 60,313 scientists (


Schizophrenia remains one of the most severe mental disorders often emerging during the vulnerable developmental phase of adolescence. Therefore, efforts at preventing psychosis, and evidence-based early treatment are crucial. Research-defined clinical high-risk states for psychosis based on mainly adult data are frequently met by adolescents, and (attenuated) psychotic symptoms may also emerge, stabilize, or progress in the context of several non-psychotic psychiatric disorders. These potentially overlapping psychopathologies with insufficient specificity for psychosis include autism-spectrum disorders, anxiety and stress-related disorders, mood disorders, emerging personality disorders, substance use disorders, and obsessive-compulsive disorders. Thus, in this early age-group at vulnerable developmental stages, the diagnostic process as well as targeted treatment of (attenuated) psychotic symptoms is challenging. Age-appropriate treatment approaches taking into account developmental stages and addressing complex symptomatology, associated burden and reduced functioning are needed. Efficacy data in youth with clinical high-risk states for psychosis are scarce and generally based on a mixture of few older adolescents as part of otherwise young adult samples. Nevertheless, data suggest that cognitive-behavioral therapy should be the first line of defense together with the evidence-based management of specific “comorbid” mental disorders. The combination with substance use or abuse can complicate the clinical picture. In case of a family history of psychosis and/or worsening severity of attenuated positive symptoms and/or functioning may make use of antipsychotics necessary, but youth re more sensitive to antipsychotic-related adverse effects, and guidance on when successful symptomatic treatment can be stopped is lacking.


Correll CU, Hauser M, Auther AM, Cornblatt BA. (2010). Standard u Research in people with psychosis risk syndrome: a review of the current evidence and future directions . J Child Psychol Psychiatry. 2010 Apr;51(4):390-431. doi: 10.1111/j.1469-7610.2010.02235.x. Epub 2010 Feb 26. PMID: 20214698; PMCID: PMC3085111.

Cornblatt BA, et al. (2015). Psychosis Prevention: A Modified Clinical High Risk Perspective From the Recognition and Prevention (RAP) Program . Am J Psychiatry. 2015 Oct;172(10):986-94. doi: 10.1176/appi.ajp.2015.13121686. Epub 2015 Jun 5. PMID: 26046336; PMCID: PMC4993209.

Lambert M, Niehaus V, Correll C. (2016) Pharmacotherapy in Children and Adolescents at Clinical-High Risk for Psychosis and Bipolar Disorder. Pharmacopsychiatry. 2016 Nov;49(6):229-244. doi: 10.1055/s-0042-116668. Epub 2016 Oct 13. PMID: 27737475.

Mei C, et al. (2021). Preventive interventions for individuals at ultra high risk for psychosis: An updated and extended meta-analysis . Clin Psychol Rev. 2021 Jun;86:102005. doi: 10.1016/j.cpr.2021.102005. Epub 2021 Mar 26. PMID: 33810885.